With second generation CARs, complete response rates of around 40% have been demonstrated in acute lymphoblastic leukemia (ALL) murine models treated with 5–10 × 106 CD19 CD28 or 4-1BB CAR T cells [82, 93, 94]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.